Anne-Marie Koop

8 301 13. Calvier L, Legchenko E, GrimmL, Sallmon H, HatchA, Plouffe BD, Schroeder C, Bauersachs J, Murthy SK, Hansmann G. Galectin-3 and aldosterone as potential tandem biomarkers in pulmonary arterial hypertension. Heart 2016;102:390–396. 14. Tang WHW, Tong W, Troughton RW, Martin MG, Shrestha K, Borowski A, Jasper S, Hazen SL, Klein AL. Prognostic Value and Echocardiographic Determinants of Plasma Myeloperoxidase Levels in Chronic Heart Failure. J Am Coll Cardiol 2007;49:2364–2370. 15. Maisel A, Mueller C, Nowak R, Peacock WF, Landsberg JW, Ponikowski P, Mockel M, Hogan C, Wu AHB, Richards M, Clopton P, Filippatos GS, Somma S Di, Anand I, Ng L, Daniels LB, Neath SX, Christenson R, Potocki M, McCord J, Terracciano G, Kremastinos D, Hartmann O, Haehling S von, Bergmann A, Morgenthaler NG, Anker SD. Mid-Region Pro- Hormone Markers for Diagnosis and Prognosis in Acute Dyspnea. Results From the BACH (Biomarkers in Acute Heart Failure) Trial. J Am Coll Cardiol Elsevier Inc.; 2010;55:2062–2076. 16. Volpe M, Carnovali M, Mastromarino V. The natriuretic peptides system in the pathophysiology of heart failure: from molecular basis to treatment. Clin Sci (Lond) 2016;130:57–77. 17. McMurray JJ, Ray SG, Abdullah I, Dargie HJ, Morton JJ. Plasma endothelin in chronic heart failure. Circulation 1992;85:1374–1379. 18. Koch A, Zink S, Singer H. B-type natriuretic peptide in paediatric patients with congenital heart disease. Eur Heart J 2006;27:861–866. 19. Albada ME Van, Loot FG, Fokkema R, Roofthooft MTR, Berger RMF. Biological serum markers in the management of pediatric pulmonary arterial hypertension. Pediatr Res 2008;63:321–327. 20. Loon RLE van, Roofthooft MTR, Delhaas T, Osch-Gevers M van, Harkel ADJ ten, Strengers JLM, Backx A, Hillege HL, Berger RMF. Outcome of Pediatric Patients With Pulmonary Arterial Hypertension in the Era of New Medical Therapies. Am J Cardiol Elsevier Inc.; 2010;106:117–124. 21. Takatsuki S, Wagner BD, Ivy DD. B-type natriuretic peptide and amino-terminal pro-B-type natriuretic peptide in pediatric patients with pulmonary arterial hypertension. Congenit Heart Dis 2012;7:259–267. 22. Ploegstra M-J, Douwes JM, Roofthooft MTR, Zijlstra WMH, Hillege HL, Berger RMF. Identification of treatment goals in paediatric pulmonary arterial hypertension. Eur Respir J 2014;1616–1626. 23. Fernandes BA, Maher KO, Deshpande SR. Cardiac biomarkers in pediatric heart disease: A state of art review. World J Cardiol 2016;8:719. 24. Baum H, Hinze A, Bartels P, Neumeier D. Reference values for cardiac troponins T and I in healthy neonates. Clin Biochem 2004;37:1079–1082. 25. Lopez L, Colan SD, Frommelt PC, Ensing GJ, Kendall K, Younoszai AK, Lai WW, Geva T. Recommendations for Quantification Methods During the Performance of a Pediatric Echocardiogram: A Report From the Pediatric Measurements Writing Group of the American Society of Echocardiography Pediatric and Congenital Heart Disease Council. J Am Soc Echocardiogr Elsevier Inc; 2010;23:465–495. 26. Simonneau G, Montani D, Celermajer DS, Denton CP, Gatzoulis MA, Krowka M, Williams PG, Souza R. Haemodynamic definitions and updated clinical classification of pulmonary hypertension. Eur Respir J 2019;53.